Clearside Biomedical, Inc. (CLSD) News & Overview - Discounting Cash Flows
CLSD
Clearside Biomedical, Inc.
CLSD (NASDAQ)

CLSD's Business Model

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Sector & Industry Healthcare / Biotechnology
Website https://www.clearsidebio.com
CEO (Chief Executive Officer) George M. Lasezkay Pharm.D., Pharma.D.
Number of Employees
IPO date June 2, 2016

CLSD Latest News

Contact
CountryUS
Address900 North Point Parkway
CityAlpharetta
StateGA
Phone678 270 3631
Zip Code30005
Other Identifiers
CIK0001539029
ISINUS1850631045
CUSIP185063104
Open0.83
Previous Close0.8123
Volume114.4 Thou.
Average Volume237.6 Thou.
Day’s Range0.81 – 0.8395
52 Week Range0.7-1.65
MA (50)0.8247
MA (200)0.97161
Market Cap63.33 Mil.
Shares Out.77.71 Mil.
Earnings DateAug 11, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for CLSD

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us